Author:
Baksh Sheriza,Zeng Lijuan
Publisher
Springer International Publishing
Reference23 articles.
1. ANVISA (2015) Resolution of the board of directors – RDC no. 9. Ministry of Health. Retrieved from http://antigo.anvisa.gov.br/documents/10181/3503972/RDC_09_2015_COMP.pdf/e26e9a44-9cf4-4b30-95bc-feb39e1bacc6
2. Buhr KA, Downs M, Rhorer J, Bechhofer R, Wittes J (2018) Reports to independent data monitoring committees: an appeal for clarity, completeness, and comprehensibility. Ther Innov Regul Sci 52(4):459–468. https://doi.org/10.1177/2168479017739268. Epub 2017 Nov 13
3. Clemens F, Elbourne D, Darbyshire J, Pocock S (2005) Data monitoring in randomized controlled trials: surveys of recent practice and policies. Clin Trials 2(1):22–33. https://doi.org/10.1191/1740774505cn064oa
4. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, ... Wright TJ (2003) Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 5(5):659–667. https://doi.org/10.1016/s1388-9842(03)00163-6
5. Combes A, Hajage D, Capellier G, Demoule A, Lavoué S, Guervilly C, ... Mercat A (2018) Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med 378(21):1965–1975. https://doi.org/10.1056/NEJMoa1800385